PMID- 25839699
OWN - NLM
STAT- MEDLINE
DCOM- 20151218
LR  - 20221207
IS  - 1533-4058 (Electronic)
IS  - 1533-4058 (Linking)
VI  - 23
IP  - 4
DP  - 2015 Apr
TI  - Detection of EML4-ALK fusion gene in Chinese non-small cell lung cancer by using 
      a sensitive quantitative real-time reverse transcriptase PCR technique.
PG  - 245-54
LID - 10.1097/PDM.0000000000000038 [doi]
AB  - Anaplastic lymphoma kinase (ALK) rearrangement is present in approximately 5% of 
      lung adenocarcinoma. Clinical trials on ALK inhibitor phase I to III have shown 
      an interesting disease control rate and acceptable tolerability in ALK 
      rearrangement patients. In clinical application, the precise diagnostic strategy 
      for identifying ALK rearrangements remains to be determined. In this study, ALK 
      rearrangement was screened by using quantitative real-time reverse transcriptase 
      polymerase chain reaction (qRT-PCR), direct sequencing, 2 fluorescence in situ 
      hybridization (FISH) assays, and immunohistochemistry in 173 lung 
      adenocarcinomas. We identified 18 cases (10.4%) with EML4-ALK fusion-positive by 
      qRT-PCR, and all were positive for EML4-ALK fusion gene validated by direct 
      sequencing. The result was consistent with that of other methods. Furthermore, of 
      the 18 EML4-ALK fusion-positive cases, 16 (9.2%) were positive by using EML4-ALK 
      fusion probe FISH, and 15 (8.7%) were positive by using ALK break-apart probe 
      FISH and immunohistochemistry staining. Of the 18 ALK fusion-positive lung 
      adenocarcinomas, 8 cases (44.4%) were histologically diagnosed as subtypes of 
      cribriform adenocarcinoma, 7 cases (38.9%) as cribriform adenocarcinoma mixed 
      with papillary and/or mucinous pattern, 2 cases (11.1%) as papillary 
      adenocarcinoma, and 1 case (5.6%) as mucinous adenocarcinoma. In the present 
      study, the ALK rearrangement frequency detected by qRT-PCR in Chinese NSCLC 
      patients was higher than that in the western populations. QRT-PCR is a rapid, 
      sensitive technology that could be used as a screening tool for identifying 
      EML4-ALK fusion-positive NSCLC patients who would be sensitive for receiving ALK 
      inhibitor therapy.
FAU - Fu, Sha
AU  - Fu S
AD  - Departments of *Molecular Diagnostics double daggerMedicine Oncology, Sun Yat-sen University 
      Cancer Center, State Key Laboratory of Oncology in South China, Collaborative 
      Innovation Center for Cancer Medicine, Guangzhou daggerScientific and Technical 
      Information of China (ISTIC), Beijing, China.
FAU - Wang, Fang
AU  - Wang F
FAU - Shao, Qiong
AU  - Shao Q
FAU - Zhang, Xu
AU  - Zhang X
FAU - Duan, Li-Ping
AU  - Duan LP
FAU - Zhang, Xiao
AU  - Zhang X
FAU - Zhang, Li
AU  - Zhang L
FAU - Shao, Jian-Yong
AU  - Shao JY
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Appl Immunohistochem Mol Morphol
JT  - Applied immunohistochemistry & molecular morphology : AIMM
JID - 100888796
RN  - 0 (EML4-ALK fusion protein, human)
RN  - 0 (Oncogene Proteins, Fusion)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Asian People
MH  - *Carcinoma, Non-Small-Cell Lung/genetics/metabolism/pathology
MH  - China
MH  - Female
MH  - Humans
MH  - *Lung Neoplasms/genetics/metabolism
MH  - Male
MH  - Middle Aged
MH  - *Oncogene Proteins, Fusion/genetics/metabolism
MH  - *Real-Time Polymerase Chain Reaction
MH  - *Reverse Transcriptase Polymerase Chain Reaction
EDAT- 2015/04/04 06:00
MHDA- 2015/12/19 06:00
CRDT- 2015/04/04 06:00
PHST- 2015/04/04 06:00 [entrez]
PHST- 2015/04/04 06:00 [pubmed]
PHST- 2015/12/19 06:00 [medline]
AID - 00129039-201504000-00002 [pii]
AID - 10.1097/PDM.0000000000000038 [doi]
PST - ppublish
SO  - Appl Immunohistochem Mol Morphol. 2015 Apr;23(4):245-54. doi: 
      10.1097/PDM.0000000000000038.